Secukinumab (Cosentyx)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Secukinumab (Cosentyx), covering 2016-02-04 to 2016-02-04. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) [Phase 3]